Presented: 21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, International Isotope Society-Central European Division, Bad Soden, Germany
By: Mr. Stephen English
Source: Xceleron, Inc., 20340 Seneca Meadows Parkway, Germantown, MD 20876, Friday, 2nd October 2015
The application of carbon isotopes (14C) and Accelerator Mass Spectrometry (AMS) in pharmaceutical clinical research has yielded significant savings in time and expense when compared with conventional isotope uses and analytical platforms. Much of these savings can be attributed to the unique advantages conferred by isotopes as microtracers and analytical sensitivity in therapeutic-level drug investigations. Growth in adoption of new isotope applications is predicated on use of robust analytical methodology. Stephen presented Xceleron’s experience in developing robust qualitative and quantitative analytical methodology to support clinical mass balance, metabolite profile and critical pharmacokinetic parameters.
Stephen also described how the combination of 14C + AMS is proving invaluable in preclinical drug research and development. He discussed the measurement of protein drug target kinetics, antibody-drug conjugate disposition and peptide metabolism as examples.
Download the presentation here
Xceleron is acquired by Pharmaron
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.